Overview

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Status:
Terminated
Trial end date:
2016-07-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study of paclitaxel plus demcizumab in subjects with platinum resistant ovarian, primary peritoneal or fallopian tube cancer.
Phase:
Phase 1
Details
Lead Sponsor:
OncoMed Pharmaceuticals, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel